Areas of Interest

Otorhinolaryngology (ENT) Partnerships

Otorhinolaryngology (ENT) Partnership Opportunities

Healthcare professionals in this area manage both acute and chronic conditions that can impact hearing, breathing, speech and overall quality of life.

Despite the clinical need in ENT care, bringing new therapies to market can present regulatory, market access and commercialisation challenges. These challenges can contribute to differences in the availability and timing of patient access across markets.

By partnering with Galen, you gain access to a team experienced in bringing market-ready and late-stage ENT products to the right markets. Our expertise in regulatory strategy, commercialisation and medical affairs allows us to support your product from due diligence through to launch and sustained market presence.

The ENT sector presents several challenges for both pharmaceutical companies and healthcare providers. The availability of medicines can be affected by a range of factors, including regulatory delays and supply and distribution challenges.1

In addition, some ENT presentations require prompt specialist assessment so timely and appropriate referrals are important.² These elements can delay diagnosis and treatment, leading to a greater burden on healthcare systems.

Pharmaceutical companies looking to bring ENT products to new or underserved markets often face regulatory complexity, supply chain hurdles and limited local market knowledge. Galen helps overcome these barriers by offering a proven commercial model, strong regulatory capabilities and established relationships with healthcare stakeholders.

Galen has a strong track record in licensing and delivering market-ready and late-stage pharmaceutical products. In the ENT space, we apply this experience to support partners seeking to expand access, navigate complex regulatory environments or strengthen commercial performance.

We work closely with our partners to develop tailored strategies that align with local market needs and healthcare priorities. Our cross-functional teams bring expertise across regulatory, medical, commercial and supply chain functions, helping to reduce time to market and support long-term product success.

By choosing Galen, you benefit from a collaborative approach focused on practical execution and measurable outcomes in the ENT area.

Galen is actively seeking late-stage or market-ready products in Otorhinolaryngology (ENT) that align with our focus on improving patient outcomes and addressing the ongoing needs of ENT specialists and their patients.

Our flexible partnership model allows us to efficiently assess, onboard and scale late-stage ENT assets, underpinned by Galen’s established experience with specialist products in this space. We combine deep market knowledge with strong regulatory, commercial and distribution capabilities to support partners from launch through long-term growth.

Contact us to explore how we can help bring your product to the right market.

References

  1. Suffolk and North East Essex Integrated Care Board (2023) Written evidence submitted to the Health and Social Care Committee’s Pharmacy inquiry (PHA0028). UK Parliament. Available at: https://committees.parliament.uk/writtenevidence/122314/pdf/ (Accessed: 12 October 2026).
  2. National Institute for Health and Care Excellence (2018) Hearing loss in adults: assessment and management. NICE guideline NG98. Available at: https://www.nice.org.uk/guidance/ng98 (Accessed: 12 October 2026).

Interested in Partnering with Us?

If you would like to explore how our expertise could add value to your product or for an initial discussion about partnering with us, get in touch today.

Contact Us

Aimee Lappin

Business Development Support Manager

Johnny McGaughey

Vice President of Business Development

Natasha Guy

Business Development Licensing Manager

If you would like to learn more about partnering with Galen, explore career opportunities, or speak with our teams, we invite you to get in touch and continue the conversation.